Capricor’s peer-reviewed publication in Biomedicines reinforced the scientific foundation of its Duchenne therapy Deramiocel, ...

Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control ...

Capricor Therapeutics (CAPR) announced the publication in Biomedicines, an international peer-reviewed journal, describing a novel in-vitro ...

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the ...

Capricor Therapeutics finds itself navigating turbulent waters as a federal securities class action lawsuit casts uncertainty over the company's future. The legal investigation, made public on October ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Capricor Therapeutics, Inc. before investing. In this article, we go over a few ...